Literature DB >> 28839955

Allosterically targeting EGFR drug-resistance gatekeeper mutations.

Nicholas Spellmon1, Chunying Li2, Zhe Yang1.   

Abstract

Entities:  

Year:  2017        PMID： 28839955      PMCID： PMC5542946          DOI： 10.21037/jtd.2017.06.43

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  7 in total

1.  The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.

Authors:  Cai-Hong Yun; Kristen E Mengwasser; Angela V Toms; Michele S Woo; Heidi Greulich; Kwok-Kin Wong; Matthew Meyerson; Michael J Eck
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-28       Impact factor: 11.205

Review 2.  Treatment of non-small-cell lung cancer with erlotinib or gefitinib.

Authors:  Vince D Cataldo; Don L Gibbons; Román Pérez-Soler; Alfonso Quintás-Cardama
Journal:  N Engl J Med       Date:  2011-03-10       Impact factor: 91.245

Review 3.  Therapeutic genome editing: prospects and challenges.

Authors:  David Benjamin Turitz Cox; Randall Jeffrey Platt; Feng Zhang
Journal:  Nat Med       Date:  2015-02       Impact factor: 53.440

4.  The conserved lysine of the catalytic domain of protein kinases is actively involved in the phosphotransfer reaction and not required for anchoring ATP.

Authors:  A C Carrera; K Alexandrov; T M Roberts
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-15       Impact factor: 11.205

5.  Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

Authors:  Kenneth S Thress; Cloud P Paweletz; Enriqueta Felip; Byoung Chul Cho; Daniel Stetson; Brian Dougherty; Zhongwu Lai; Aleksandra Markovets; Ana Vivancos; Yanan Kuang; Dalia Ercan; Sarah E Matthews; Mireille Cantarini; J Carl Barrett; Pasi A Jänne; Geoffrey R Oxnard
Journal:  Nat Med       Date:  2015-05-04       Impact factor: 53.440

6.  WHSC1L1-mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR in head and neck cancer.

Authors:  Vassiliki Saloura; Theodore Vougiouklakis; Makda Zewde; Xiaolan Deng; Kazuma Kiyotani; Jae-Hyun Park; Yo Matsuo; Mark Lingen; Takehiro Suzuki; Naoshi Dohmae; Ryuji Hamamoto; Yusuke Nakamura
Journal:  Sci Rep       Date:  2017-01-19       Impact factor: 4.379

7.  Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.

Authors:  Yong Jia; Cai-Hong Yun; Eunyoung Park; Dalia Ercan; Mari Manuia; Jose Juarez; Chunxiao Xu; Kevin Rhee; Ting Chen; Haikuo Zhang; Sangeetha Palakurthi; Jaebong Jang; Gerald Lelais; Michael DiDonato; Badry Bursulaya; Pierre-Yves Michellys; Robert Epple; Thomas H Marsilje; Matthew McNeill; Wenshuo Lu; Jennifer Harris; Steven Bender; Kwok-Kin Wong; Pasi A Jänne; Michael J Eck
Journal:  Nature       Date:  2016-05-25       Impact factor: 49.962
  7 in total
  1 in total

1.  Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer.

Authors:  Meredith S Eno; Jason D Brubaker; John E Campbell; Chris De Savi; Timothy J Guzi; Brett D Williams; Douglas Wilson; Kevin Wilson; Natasja Brooijmans; Joseph Kim; Ayşegül Özen; Emanuele Perola; John Hsieh; Victoria Brown; Kristina Fetalvero; Andrew Garner; Zhuo Zhang; Faith Stevison; Rich Woessner; Jatinder Singh; Yoav Timsit; Caitlin Kinkema; Clare Medendorp; Christopher Lee; Faris Albayya; Alena Zalutskaya; Stefanie Schalm; Thomas A Dineen
Journal:  J Med Chem       Date:  2022-07-15       Impact factor: 8.039
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.